Results 191 to 200 of about 181,985 (340)

Pharmacokinetic and pharmacodynamic studies of piretanide in rabbits. II: Effects on the proximal tubules and the loop of Henle.

, 1988
Wei Lu, Makiko ENDOH, Kazunori Katayama, Masawo Kakemi, TAMOTSU KOIZUMI   +4 more
openalex   +2 more sources

Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate [PDF]

, 1984
H C Blossey, Hans Erik Wander, Johannes Koebberling, Gerd Nagel   +3 more
openalex   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi, Ji Yun Kim, Lisa Seitz, Lixia Jin, Paul G. Foster, Kai H. Liao, Tzuling Cheng, Elaine Paterson, Maria Velinova, Nicole Rivera Rosario, Reza Khosravan, Balaji Agoram   +11 more
wiley   +1 more source

PHARMACOKINETICS AND PHARMACODYNAMICS OF ORG NC 45 IN PATIENTS WITH CIRRHOSIS [PDF]

, 1982
P. Duvaldestin, J.L. Berger, M. Videcoq, J. M. Desmonts   +3 more
openalex   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, Manjunath S. Shet, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. [PDF]

J Pharmacokinet Pharmacodyn
Derbalah A, Stader F, Liu C, Zyla A, Abdulla T, Wu Q, Jamei M, Gardner I, Sepp A.   +8 more
europepmc   +1 more source

Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning

British Journal of Clinical Pharmacology, EarlyView.
Aims In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan‐based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death.
Beth Apsel Winger, Joseph W. Polli, Janel Long‐Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian   +6 more
wiley   +1 more source

Optimal Control in Combination Therapy for Heterogeneous Cell Populations with Drug Synergies. [PDF]

Bull Math Biol
Martina-Perez SF, Johnson SWS, Crossley RM, Kasemeier JC, Kulesa PM, Baker RE.   +5 more
europepmc   +1 more source

Therapeutic drug monitoring education: The current state

British Journal of Clinical Pharmacology, EarlyView.
Aims To evaluate available information on therapeutic drug monitoring (TDM) education programmes and their implementation across different countries. Methods The study was performed in two phases. First, a scoping review of scientific literature on available education programmes was performed.
Guenka Petrova, Stiliyana Blagova, Konstantin Tachkov, Marlene Santos, James Bluett, Merita Rumano, Elena Kkolou, Elena Drakalska, Marija Arev, Mehtap Cakmak Barsbay, Denis Mulleman   +10 more
wiley   +1 more source

Letter to the Editor: The Pharmacological Responsibility Chain - Mapping Competence Toward Responsible Prescribing. [PDF]

Hosp Pharm
Fajkić A, Belančić A, Vitezić D.
europepmc   +1 more source